Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma

Br J Haematol. 2003 Jan;120(2):304-9. doi: 10.1046/j.1365-2141.2003.04054.x.

Abstract

The feasibility of allogeneic haematopoietic stem-cell transplantation (allo-HSCT) in 11 patients with adult T-cell leukaemia/lymphoma (ATL) (6 acute, 4 lymphoma, 1 chronic type) was evaluated. The preparative regimens (9 conventional, 2 reduced-intensity) were tolerable. Five patients developed acute graft-versus-host disease (GVHD), and three, extensive chronic GVHD. All 10 patients who survived > 30 d achieved complete remission. Estimated 1-year overall and disease-free survival rates were 53 +/- 30% and 45 +/- 29% respectively. Four patients remain alive and disease-free at a median follow-up of 25 months. The others died of transplantation-related complications. This pilot study suggests that allo-HSCT in ATL should be evaluated further.

MeSH terms

  • Acute Disease
  • Chronic Disease
  • Feasibility Studies
  • Female
  • Follow-Up Studies
  • Graft vs Host Disease
  • Graft vs Leukemia Effect
  • Hematopoietic Stem Cell Transplantation / methods*
  • Hematopoietic Stem Cell Transplantation / mortality
  • Humans
  • Leukemia-Lymphoma, Adult T-Cell / mortality
  • Leukemia-Lymphoma, Adult T-Cell / surgery*
  • Male
  • Middle Aged
  • Survival Rate
  • Transplantation, Homologous
  • Treatment Outcome